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Acquired drug resistance is a major problem in cancer treatment. To explore the genes involved in chemosensitivity and resistance,
10 human tumour cell lines, including parental cells and resistant subtypes selected for resistance against doxorubicin, melphalan,
teniposide and vincristine, were profiled for mRNA expression of 7400 genes using cDNA microarray technology. The drug activity
of 66 cancer agents was evaluated on the cell lines, and correlations between drug activity and gene expression were calculated and
ranked. Hierarchical clustering of drugs based on their drug–gene correlations yielded clusters of drugs with similar mechanism of
action. Genes correlated with drug sensitivity and resistance were imported into the PathwayAssist software to identify putative
molecular pathways involved. A substantial number of both proapoptotic and antiapoptotic genes such as signal transducer and
activator of transcription 1, mitogen-activated protein kinase 1 and focal adhesion kinase were found to be associated to drug
resistance, whereas genes linked to cell cycle control and proliferation, such as cell division cycle 25A and signal transducer of
activator of transcription 5A, were associated to general drug sensitivity. The results indicate that combined information from drug
activity and gene expression in a resistance-based cell line panel may provide new knowledge of the genes involved in anticancer drug
resistance and become a useful tool in drug development.
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Chemotherapy is an important modality for the treatment of
malignant tumours. However, for the majority of cancer patients,
treatment with established anticancer drugs produces dissatisfac-
tory long-term effects and drug activity is highly variable both
between and within different diagnoses (Nygren, 2001). Genes
affecting chemosensitivity are involved in drug transport, drug
metabolism, DNA synthesis and repair, cell survival and apoptosis
(Marie, 2001; Pommier et al, 2004). Since many different signalling
pathways are involved, there is an urgent need for high-efficacy
drugs with novel mechanisms of action targeting the key genes.
Rapid cell-based methods for high-throughput and focused
screening based on drug-response analysis in a panel of cell lines
have proven to be important tools in anticancer drug discovery
and early evaluation (Paull et al, 1989; Boyd and Paull, 1995; Dhar
et al, 1996; Weinstein et al, 1997). Research performed at the
National Cancer Institute (NCI) has shown that a drug activity
profile acquired from a nonclonogenic growth inhibition assay on
a panel of 60 parental human cancer cell lines can provide
important information on the mechanism of action of various
compounds. Robust and accurate mechanistic drug–drug relation-
ships have repeatedly been demonstrated using both simple
correlation analysis and more sophisticated data analytical
methods (Paull et al, 1989; Weinstein et al, 1992, 1997; Boyd and
Paull, 1995). We have previously shown that, by applying similar
techniques, a smaller panel of 10 cell lines representing different
drug-resistant phenotypes could accomplish accurate classifica-
tions of mechanisms of action for common anticancer drugs (Dhar
et al, 1996).
The development of novel molecular technologies such as cDNA
microarrays has made it possible to identify genes involved in
chemosensitivity. Integration of gene expression and drug activity
data sets for cancer cells can identify relationships between
individual genes and sensitivity or resistance to specific drugs.
Investigators at NCI analysed the gene expression profiles of the
NCI human tumour cell line panel and correlated the gene
expression to growth-inhibitory activity of anticancer compounds
(Scherf et al, 2000).
Several genes were identified which could be considered as
candidate targets or biomarkers for chemosensitivity. The
approach was considered feasible and useful for exploring the
mechanisms of action, and was supported by investigators
applying a similar methodology on a 39-cell line panel (Dan
et al, 2002). The cell lines used in these studies consisted of
parental cells of different cancer types and did not include any
selected resistant phenotypes. With the aim of identifying
chemosensitivity genes, the inclusion of resistant cell lines may
be advantageous by increasing the range of expression in the
measured microarray data, specifically for the genes involved in
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sdevelopment of resistance. Therefore, in the present study, a cell
line panel representing different drug resistance phenotypes,
rather than histological origin, was characterised with respect to
gene expression and anticancer drug response, and the relation-
ships between the resulting drug and gene expression profiles were
subsequently explored. By association analyses using pathway
mining software, molecular pathways putatively involved in drug
resistance and sensitivity were identified.
MATERIALS AND METHODS
Cell culture
The human cancer cell line panel has been described previously
(Dhar et al, 1996). The panel consists of the parental cell lines
RPMI 8226 (myeloma), CCRF-CEM (leukaemia), U937-GTB
(lymphoma) and NCI-H69 (small-cell lung cancer); the drug-
resistant sublines 8226/Dox40 8226/LR5, CEM/VM-1, U937/vcr,
H69AR and the primary resistant ACHN (renal adenocarcinoma).
8226/Dox40 was exposed to 0.24mgml
 1 of doxorubicin once a
month, and overexpresses Pgp/MDRl/ABCBl (Dalton et al, 1986).
8226/LR5 was exposed to 1.53mgml
 1 of melphalan at each change
of medium, and the resistance is proposed to be associated with
increased levels of glutathione as well as genes involved in cell
cycle and DNA repair (Bellamy et al, 1991; Mulcahy et al, 1994;
Hazlehurst et al, 2003). U937 vcr was continuously cultured in the
presence of 10ngml
 1 vincristine, and the resistance is proposed
to be rubulin associated (Botling et al, 1994). H69AR was
alternately fed with drug-free medium and medium containing
0.46mgml
 1 of doxorubicin, and overexpresses MRP1/ABCC1
(Mirski et al, 1987; Cole et al, 1992; Slovak et al, 1993). CEM/
VM-1 was cultured in drug-free medium and could be grown for
3–4 months without loss of resistance against teniposide, which is
proposed to be topoisomerase II associated (Danks et al, 1987,
1988; Mao et al, 1999). The primary drug resistance of ACHN is
probably multifactorial (Nygren and Larsson, 1991). All cells were
grown in culture medium RPMI-1640 supplemented with 10%
heat-inactivated foetal calf serum, 2mM glutamine, 100mgml
 1
streptomycin and 100Uml
 1 penicillin (all from Sigma Aldrich
Co, St Louis, MO, USA) at 371C in humidified air containing 5%
CO2. The resistant cell lines were tested regularly for maintained
resistance to the selected drugs. Growth and morphology of all cell
lines were monitored on a weekly basis.
Measurement of drug activity
A total of 66 anticancer drugs (Table 1), obtained from commercial
sources or from NCI, were dissolved according to the manufac-
turer’s instructions and tested in five concentrations, obtained by
10-fold serial dilution. The investigational alkylating agents Jl and
P2 were kind gifts from Oncopeptides AB (Stockholm, Sweden).
The Fluorometric Microculture Cytotoxicity Assay (FMCA),
described in detail previously (Larsson et al, 1990), is based on
measurement of fluorescence generated from hydrolysis of
fluoroscein diacetate (FDA) to fluorescein by cells with intact
plasma membranes. Briefly, cells were seeded into microtitre plates
(Nunc, Roskilde, Denmark) prepared with drugs and incubated at
371C and 5% CO2. for 72h. Then the plates were washed, FDA
added, and, after 40min of incubation, the fluorescence was
measured in a Fluoroscan II (Labsystems Oy, Helsinki, Finland).
The fluorescence is proportional to the number of living cells and
data are presented as survival index, defined as the fluorescence of
experimental wells in percent of control wells with blank values
subtracted. The IC50 value for each drug in each cell line was
obtained from concentration–response curves constructed in
Excel (Microsoft) and GraphPadPrism (GraphPad Software Inc.,
CA, USA).
RNA extraction and reference composition
Total RNA was extracted from each cell line starting from 10 cells,
using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s protocol. The purity of the RNA was ensured
by measuring the optical density at 260 and 280nm. The integrity
of the RNA was controlled by capillary electrophoresis using a
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). Only
pure RNA (OD 260/280 41.8) without any sign of degradation was
used in the subsequent experiments. The common reference RNA
used in the array experiments was composed of equal aliquots
from the cell lines HELA, ACHN, U937-GTB, HTERT-RPE and
H69AR.
Array fabrication
In all, 7458 cDNA clones, included in the Human Sequence
Verified Set, were obtained from Research Genetics (Huntsville,
AL, USA). A complete list of genes printed on the arrays is
available at: http://www.genpat.uu.se/Forskargrupper/wcn/UU/In-
strAndProd_section.htm#prod. Plasmids containing clones were
grown in Escherichia coli overnight in 96-well microtitre plates.
Plasmid DNA was isolated using the Millipore Plasmid Miniprep96
Kit (Millipore, Bedford, MA, USA) and clone inserts were
amplified using vector-specific primers (Universal Forward 50-
CTGCAAGGCGATTAAGTTGGGTAAC-30 and Universal Reverse
50-GTGAGCGGATAACAATTTCACACAGGAAACAGC-30). The PCR
products were purified with the Millipore Multiscreen PCR
96-well plate filtration system (Millipore) and dissolved in 45ml
MilliQ-water. The PCR products were dried and re-suspended in
MilliQ-water, containing 30% DMSO, to a final concentration of
0.1mgml
 1. The PCR products were printed with a Cartesian
Prosys 5510A (Cartesian Technologies Inc., Irvine, CA, USA) in
duplicates with eight 3B Stealthpins (TeleChem International Inc.,
Sunnyvale, CA, USA) on GAPSII slides (Corning Life Sciences,
Table 1 Anticancer drugs used in the study
Antimetabolites
Acivicin, Aminopterin, Aphidicolin, 5-Azacytidine, L-Alanosine , Cladribine,
Cyclocytidine, Cytarabine, 3-Deazauridine, 2-Azacytidine, Diglycoaldehyde,
Fludarabine, 5-Fluorouracil, Ftorafur, Hydroxyurea, 6-Mercaptopurine
Methotrexate, PALA, Pentostatin, 6-Thioguanine, Thymidine
Alkylating agents
Busulfan, Carboplatin, Chlorambucil, Cisplatin, 4-HC, J1, Mechlorethamine,
Melphalan, Mitomycin C, P2, Sarcolysine
Topoisomerase I-inhibitors
Camptothecin, SN-38, Topotecan
Topoisomerase II-inhibitors
Amsacrine, Bisantrene, Daunorubicin, Doxorubicin, Epirubicin, Etoposide,
Idarubicin, Mitoxantrone Teniposide
Proteasome inhibitors
Bortezomib, Lactacystin, MG-132, MG-262
Tubulin active agents
Colchicine, Docetaxel, Maytansine, Paclitaxel, Podophyllotoxin, Vinblastine,
Vincristine, Vindesine, Vinorelbine, Estramustine
Others
Aclarubicin, Anguidine, Cycloheximide, Flavoneacetate, Hoechst 33342, MBGB,
MIBG, Spirogermanium
PALA¼N-phosphonacetyl-L-aspartate; 4-HC¼4-hydroperoxy-cyclophosphamide;
MGBG¼methylglyoxal-bis(guanylhydrazone); MIBG¼meta-iodobenzylguanidine;
SN-38¼active metabolite of camptothecin; J1 and P2, oligopeptide derivatives of
melphalan and sarcolysine, respectively.
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sActon, MA, USA). The printing temperature was 251C and the
relative humidity 65%. The spotted PCR products were crosslinked
to the slides at 450mJ using a Stratalinker UV 1800 (Stratagene, La
Jolla, CA, USA).
Probe preparation, hybridisation, development and image
acquisition
Labelling and detection of cDNA were carried out using the TSA
Labelling and Detection Kit (NEN Life Science Products, Boston,
MA, USA). The TSA probe labelling, array hybridisation and
development were performed as described previously (Karsten
et al, 2002). The microarrays were scanned in a GenePix 4000B
scanner (Axon Instruments, Union City, CA, USA) at wavelengths
635 and 532nm for Cy5 and Cy3 dyes, respectively, using 10-mm
resolution.
Image processing and normalisation and filtering
The images were analysed and raw data were extracted, using
GenePix Pro software version 5.0. (Axon Instruments). Raw data
were normalised using the SMA package (Statistics for Microarray
Analysis: http://www.stat.berkeley.edu/users/terry/zarray/Software/
smacode.html). The algorithm used was LOWESS print tip
normalisation (Yang et al, 2002). Each cell line was analysed on
two separate arrays with the dyes reversed, providing a total of
four (genes printed in duplicates on each array) measurements per
gene and cell line. Genes with missing values for more than half of
the cell lines were removed from the data set. This filter reduced
the number of genes from 7458 to 3903. For genes passing this
filtering criteria, an average expression level for each gene and
sample was calculated and used in further analysis.
Data analysis
The drug- and gene-expression databases were integrated and a
correlation analysis performed in a custom-made program with
similar functions as COMPARE (http://www.nci-sw. com/compar-
e.html). Pearson’s correlation coefficients for all drug–drug (log10
IC50), gene–gene (log2) and drug–gene correlations (log10, log2)
were automatically calculated and stored in this database.
Differential drug activity and differential gene expression were
displayed in delta graphs. The cell line panel mean log10 IC50 or
log2 gene-expression values were determined and subtracted from
the log10 or log2 values for each cell line to yield the variable
defined as delta. Unsupervised hierarchical cluster analysis for
cells–genes, cells–drugs and genes–drugs was performed with the
CIMminer software (http://discover.nci.nih.Kov/nature2000/tools/
cimmaker.isp) using average linkage clustering with Pearson’s
correlation coefficient as the measure of similarity. A correlation
coefficient above 0.7 or below -0.70 was chosen to extract the genes
specifically associated with drug sensitivity and resistance,
respectively. This level of Pearson’s correlation coefficient
corresponds to a significance level of Po0.05 for a two-tailed test
for 10 observation pairs of the null hypothesis that the correlation
is zero.
Identification of molecular pathways
The genes connected to general chemosensitivity and resistance
were analysed using PathwayAssist software to identify signalling
pathways (Pathway assist v3.0. (www.ariadnegenomics.com).
PathwayAssist is a software for visualisation and exploration of
biological pathways, gene regulation networks and protein–
protein interactions. PathwayAssist is supplied with ResNet
molecular interaction and pathway database, which contains more
than 500000 functional links for more than 50000 proteins,
extracted from more than 5000000 Medline abstracts and full-
length articles (ResNet update Q4 2004).
RESULTS
Analysis of the gene expression and drug activity data sets
A cDNA microarray analysis was performed to investigate the
expression profiles of the 7458 genes in each of the 10 cell lines. Of
these genes, 3903 fulfilled the preset quality criteria for subsequent
analyses. An example is shown in Figure 1, in which the accurate
detection of the ABCC1 transporter in the cell lines is shown. In
general, cDNA microarray expression data need to be validated to
ensure that the correct gene expression has been measured. In this
case, oligonucleotide arrays with a shorter more specific probe has
been used to validate MRPl/ABCCl expression (correlation
coefficient r40.9, data not shown). H69AR showed an increased
expression of MRPl/ABCCl compared to all other cell lines, which
is consistent with previous results, further supporting the validity
of the array measurements (Cole et al, 1992). A hierarchical
clustering method was then applied to the gene expression in the
cell lines (Figure 2). The parental cell lines clustered with their
resistant sublines, indicating that no gross alteration in the gene
expression profile resulted from the selection of the drug-resistant
sublines. Next, correlations were established between the log2
expression values of each of these 3903 genes and the log10 IC50
values obtained for each of the 66 drugs included in the study.
Hierarchical clustering of drugs based on these drug–gene
correlations resulted in clusters consisting of drugs with similar
modes of action (Figure 3). All proteasome inhibitors and
topoisomerase I (Topi) inhibitors and most of the antitubulins,
topoisomerase II (Top2) inhibitors and alkylating agents formed
distinct clusters. Notable exceptions were the tubulin active agents
vindesine and estramustine, which did not cluster within their
assigned mechanistic group. The antimetabolites clustered more
heterogeneously, but closely related drugs with respect to
mechanism of action, such as the dihydrofolate reductase
inhibitors methotrexate and aminopterin, clustered together. Also,
Jl and P2, oligopeptide derivatives of melphalan and sarcolysine,
respectively, did not cluster with their parent compounds.
Clustering of drugs based on drug activity alone yielded similar
results as the clustering based on the drug–gene correlations (data
not shown). An example of a typical drug–gene relationship is
shown in Figure 4 Concentration–response curves for doxorubicin
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Figure 1 Differential expression of MRP1/ABCC1 in the cell line panel.
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Figure 2 Two-dimensional hierarchical clustering analysis based on similarities in gene expression in the cell lines.
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Figure 3 Two-dimensional hierarchical clustering analysis based on drug–gene correlations (Pearsons correlation coefficients) for drug response data
(log10 IC50) of 66 anticancer drugs and 3903 genes (log2) in the 10 cell lines.
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sin the cell line panel and delta graphs for differential drug activity
and STAT1 gene expression are depicted in panels A–C,
respectively. The activity (log10 IC50) of doxorubicin and the
expression of STAT1 (log2) in the cell lines were highly correlated
(panel D, R¼0.89). Table 2 displays the 40 genes with the highest
positive and negative correlations to doxorubicin.
Identification of signalling pathways associated to drug
sensitivity and resistance
Genes where R40.70. and o 0.70 were extracted for each of the
66 drugs (supplementary information online). A correlation
coefficient of 40.70 or o 0.70 in at least 20 of the 66 drugs
was set as the criterion for the selection of genes associated to
chemosensitivity. This selection identified 122 and 74 genes
correlated to general resistance and sensitivity, respectively. Next,
Pathway Assist was used in two steps to explore the interactions
between the genes on the two lists. In the first step, the ResNet
database was searched to establish direct interactions between the
genes, and, in the second step, the genes were searched for linkage
to cellular processes involving cellular proliferation, cell survival,
cell death or apoptosis. The genes selected in this way to form
these molecular networks are listed in Tables 3 and 4. The two
networks are accessible in supplementary information online as
html web files, and the connections are clickable (dots on lines) to
access hyperlinks to the Medline references on which the networks
are based. Clicking on the nodes provides hyperlinks to several
gene and protein databases, including HUGO, OMIM, Locus Link
and Swiss-Prot for the particular protein. A simplified version of
the network for genes associated with drug resistance is shown in
Figure 5. Regarding genes associated to sensitivity, there was a
considerable number that could be linked to cell cycle and
proliferation regulation rather than apoptosis, including genes
such as CDC25A, CCNC, CCND3 and STAT5A (Figure 5A).
Notably, for the resistance associated genes, both known
proapoptotic and antiapoptotic pathways were detected in the
resulting network (Figure 5B). In this molecular network, caspase 3
and 6 and Jun were identified together with survival genes such as
RB1, calpastatin, PTK2 and MAPK.1. These gene/pathway maps
may provide novel potential molecular targets for therapy. In
addition to the genes selected by Pathway Assist, several other
potentially relevant genes fulfilled the general resistance and
sensitivity criteria including ABC transporters, drug-inactivating
enzymes and protein kinases (for complete general sensitivity and
resistance lists, see the supplementary information online).
DISCUSSION
Gene–drug relationships in large panels of cancer cell lines with
different histological origins have been studied previously (Scherf
et al, 2000; Dan et al, 2002). In the present study, we studied the
gene expression and drug activity in a panel of 10 cell lines
representing different mechanisms of anticancer drug resistance.
Previous studies have shown that drug activity patterns in this
panel can be used to classify anticancer drugs according to
mechanism of action (Dhar et al, 1996). Here we showed that this
classification also corresponded to identifiable patterns of gene
expression and that the genes which correlated to drug sensitivity
and resistance seem to be biologically relevant. The gene-
expression profiles of the cell lines were similar for cells with the
same histological origin and the hierarchical clustering performed
based on drug–gene correlations for the drugs in the cell lines
yielded clusters of drugs based on their main mechanism of action,
with some exceptions. There are several possible reasons for
incorrect clustering, and these include experimental variability and
incorrect or incomplete assignment of the mechanism of action.
Concerning the antimetabolites, the clustering was not clearly
linked to known structural or mechanistic features. Given the very
diverse mechanistic properties of these drugs, this was not an
unexpected finding. Other drugs that deviated from the expected
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Figure 4 An example of the drug–gene correlations obtained.
Concentration–response curves for doxorubicin in the cell line panel
(A). Correlation between log2 expression of STAT1 with log IC50 of
doxorubicin (B). Mean graphs of doxorubicin (C) and STAT1 (D).
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sclustering were vindesine, estramustine, J1 and P2. As an example,
Jl and P2, oligopeptide derivatives of melphalan and sarcolysine,
respectively, clustered together, but differently from their parent
compounds. Jl is currently undergoing clinical development, and
recent studies have indicated other mechanisms of cell death
additional to the death caused by DNA alkylation (Gullbo et al,
2003). The overall results indicate that the panel of 10 tumour cell
lines was able to reasonably well classify drugs with respect to the
mechanism of action.
The mechanistic pathways identified with PathwayAssist asso-
ciated to general drug resistance paradoxically included a
substantial number of both proapoptotic and antiapoptotic genes.
The proapoptotic genes caspase 3 and 6 (CASP3, 6) and Jun were
identified together with survival genes such as retinoblastoma 1
(RBI), calpastatin (CAST), focal adhesion kinase/protein tyrosine
kinase 2 (FAK/PTK2) and mitogen-activated protein kinase 1
(MAPK1). A parallel upregulation of pro- and antiapoptotic genes
in malignant tumours has been observed in several microarray
studies comparing tumour cells and normal tissue (Rhodes et al,
2004; www.oncomine.com), indicating that the balance between
upregulated pro- and antiapoptotic genes may be critical for
tumour cell survival. To affect this balance by small molecules may
thus be a potential therapeutic strategy. The expression of signal
transducer and activator of transcription 1 (STATl) was also
observed to be highly correlated to resistance, particularly for the
Top2 inhibitors (data not shown). Although activation of STATl in
some cell systems has been shown to be proapoptotic (Calo et al,
2003), a recent observation has indicated a role for STATl in
mediating radiation resistance (Khodarev et al, 2004). Recently, a
correlation between STATl expression and cisplatin resistance in
cell lines derived from patients with ovarian carcinoma was also
reported (Roberts et al, 2005), and inhibitors of the STATl pathway
have been shown to induce apoptosis in leukaemic cells from
patients (Martinez-Lostao et al, 2005). The pathway analysis
showed that STATl is positively influenced by MAPK1 and FAK,
two of the most highly connected resistance-associated genes, both
of which have been reported to inhibit apoptosis (Shimada et al,
2002; Kurenova et al, 2004). Notably, STATl expression has been
reported higher in tumour compared with corresponding normal
tissue for a wide range of tumour types (www.oncomine.com). The
STATl pathway may thus provide a potentially interesting drug
target for reversal of drug resistance.
The genes correlated to drug sensitivity had diverse functions,
but a considerable number were found to be related to cell cycle
and proliferation rather than to apoptosis, for example, cell
division cycle 25A (CDC25A) and signal transducer of activator of
transcription 5A (STAT5A). This is in accordance with the general
notion of a correlation between high proliferation and increased
anticancer drug sensitivity (Valeriote and van Putten, 1975; Kaaijk
et al, 2003).
Table 2 The genes with highest positive and negative correlations to doxorubicin
Symbol Acc ID Name R
CTTN M98343 Cortactin 0.96
SLC39A1 BC047288 Solute carrier family 39 (zinc transporter), member 1 0.93
TTF2 NM_003594 Transcription termination factor, RNA polymerase II 0.93
TPI1 BM913099 Triosephosphate isomerase 1 0.93
DDAH1 NM_012137 Dimethylarginine dimethylaminohydrolase 1 0.92
EXTL1 NM_004455 Exostoses (multiple)-like 1 0.92
GNA11 BC063426 Guanine nucleotide binding protein (G protein), alpha 11 0.92
MAPK11 BC027933 Mitogen-activated protein kinase 11 0.92
SURB7 NM_004264 SRB7 suppressor of RNA polymerase B homolog (yeast) 0.91
HLA-DOA NM_002119 Major histocompatibility complex, class II, DO alpha 0.90
STAT1 NM_007315 Signal transducer and activator of transcription 1, 91kDa 0.89
AGRN AB191264 Agrin 0.89
PTTG1IP AK095586 Pituitary tumour-transforming 1 interacting protein 0.89
FXYD1 AK124802 FXYD domain containing ion transport regulator 1 0.88
DRPLA BC051795 Dentatorubral-pallidoluysian atrophy 0.88
TULP3 NM_003324 Tubby like protein 3 0.88
BCAR1 AK124526 Breast cancer anti-oestrogen resistance 1 0.88
SPAG9 AF327452 Sperm associated antigen 9 0.87
ABCB6 BC043423 ATP-binding cassette, subfamily B (MDR/TAP), member 6 0.87
CAST NM_173060 Calpastatin 0.87
BNIP2 AK125533 BCL2/adenovirus E1B 19kDa interacting protein 2  0.97
GCAT AK123190 Glycine C-acetyltransferase  0.92
TIMM10 BQ011318 Translocase of inner mitochondrial membrane 10 homolog (yeast)  0.91
RNUT1 BG421329 RNA, U transporter 1  0.90
ASCC3 AL834463 DJ467N11.1 protein  0.90
GAS7 NM_201433 Growth arrest-specific 7  0.88
CORO1A AK123401 Coronin, actin-binding protein, 1A  0.88
LCP2 NM_005565 Lymphocyte cytosolic protein 2  0.88
WAS BM455138 Wiskott–Aldrich syndrome  0.88
EBP BE253850 Emopamil-binding protein  0.88
PSD4 BC073151 Pleckstrin and Sec7 domain containing 4  0.87
KIAA1545 AB046765 KIAA1545 protein  0.87
IDH3A AK123316 Isocitrate dehydrogenase 3 (NAD+) alpha  0.87
NIPBL AJ627032 Nipped-B homolog (Drosophila)  0.86
POLQ NM_006596 Polymerase (DNA directed), theta  0.86
C15orf22 AK075529 Chromosome 15 open reading frame 22  0.85
RAC2 AK096924 Ras-related C3 botulinum toxin substrate 2  0.85
PHF2 NM_005392 PHD finger protein 2  0.85
TPBG NM_006670 Trophoblast glycoprotein  0.85
ARHGDIB AK125625 Rho GDP dissociation inhibitor (GDI) beta  0.84
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sSome limitations of the study should be discussed. First, cell
lines removed from their in vivo environment and selected for
growth in culture differ from tumour cells in patients. Therefore,
the relevance of the genes and mechanistic pathways needs to be
studied in additional settings, such as primary cultures of tumour
cells from patients. Second, the drug activity database was
generated using a single assay end point, that is, short-term
growth inhibition and cytotoxicity. Drugs may induce concentra-
tion-dependent effects on different targets leading to different
modes of cell death, including apoptosis, necrosis and cell
senescence (Blagosklonny, 2004). Multiparameter assays using
high-content screening may provide a substantial increase in the
information on drug activity and mode of cell death (Lo ¨vborg et al
2004), and such studies are underway. Third, only a part of all
human genes were represented on the arrays used. Also, the gene–
drug relationships described represent only a small fraction of
relationships thought to be relevant to chemotherapy, and many
are probably hidden by the arbitrary and rough cutoff criteria that
need to be applied for selection of the information, among all the
available microarray data, considered to be relevant. Fourth, with
respect to the data exploration, the quality of the data obtained is
dependent on the information and algorithms in the software used,
meaning that these data should only be used for generation of
hypotheses that need further and direct confirmation. Finally,
although this exploitation of array data using powerful software
can provide a basis for identification of new drug targets, it should
be emphasised that the relationships observed are correlative, not
Table 3 Genes associated with drug resistance selected by PathwayAssist
Symbol Name
AGRN Agrin
APP Amyloid beta (A4) precursor protein (protease nexin-II,
Alzheimer’s disease)
BACE2 Beta-site APP-cleaving enzyme 2
BAG3 Bcl2-associated athanogene 3
BASP1 Brain abundant, membrane-attached signal protein 1
BCAR1 Breast cancer antioestrogen resistance 1
BMPR1A Bone morphogenetic protein receptor, type IA
CASP3 Caspase 3, apoptosis-related cysteine protease
CASP6 Caspase 6, apoptosis-related cysteine protease
CAST Calpastatin
CD9 CD9 antigen (p24)
CKAP4 Cytoskeleton-associated protein 4
CREBBP CREB-binding protein
CSPG2 Chondroitin sulphate proteoglycan 2 (versican)
CTTN Cortactin
DAG1 Dystroglycan 1 (dystrophin-associated glycoprotein 1)
DDAH1 Dimethylarginine dimethylaminohydrolase 1
DRPLA Dentatorubral-pallidoluysian atrophy (atrophin-1)
EPHA2 EphA2
FXYD1 FXYD domain containing ion transport regulator 1
(phospholemman)
HIF1A Hypoxia-inducible factor 1, alpha subunit (basic helix–loop–
helix transcription factor)
IGSF4 Immunoglobulin superfamily, member 4
ITGAV Integrin, alpha V (vitronectin receptor, alpha polypeptide,
antigen CD51)
ITPR3 Inositol 1,4,5-triphosphate receptor, type 3
ITSN1 Intersectin 1 (SH3 domain protein)
JUN Jun oncogene
LTBP1 Latent transforming growth factor beta binding protein 1
MAFG V-maf musculoaponeurotic fibrosarcoma oncogene homologue
G (avian)
MAP4K3 Mitogen-activated protein kinase kinase kinase kinase 3
MAPK1 Mitogen activated protein kinase 1
MAPK11 Mitogen-activated protein kinase 11
MDK Midkine (neurite growth-promoting factor 2)
NBL1 Neuroblastoma, suppression of tumorigenicity 1
NEFL Neurofilament, light polypeptide 68kDa
PAWR PRKC, apoptosis, WT1, regulator
PEA15 Phosphoprotein enriched in astrocytes 15
PLXNB1 Plexin B1
POR P450 (cytochrome) oxidoreductase
PTK2 PTK2 protein tyrosine kinase 2
PTPN13 Protein tyrosine phosphatase, nonreceptor type 13
PXN Paxillin
RB1 Retinoblastoma 1
RDX Radixin
RIPK2 Receptor-interacting serine–threonine kinase 2
S100A10 S100 calcium-binding protein A10 (annexin II ligand, calpactin I,
light polypeptide (p11))
SERPINH1 Serine (or cysteine) proteinase inhibitor, clade H (heat shock
protein 47), member 1 (collagen-binding protein 1)
STAT1 Signal transducer and activator of transcription 1
TPI1 Triosephosphate isomerase 1
TRA1 Tumour rejection antigen (gp96) 1
TUBB Tubulin, beta polypeptide
TULP3 Tubby like protein 3
The listed genes were selected by the PathwayAssist software as described in the
Results section. An interactive graphical version is available in the supplementary
information online.
Table 4 Genes associated with drug sensitivity selected by Pathway-
Assist
Symbol Name
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta
BCCIP BRCA2 and CDKN1A interacting protein
CCNC Cyclin C
CCND3 Cyclin D3
CD37 CD37 antigen
CD4 CD4 antigen
CDX2 Caudal type homeo box transcription factor 2
CKLF Chemokine-like factor
CORO1A Coronin, actin-binding protein, 1A
DOCK2 Dedicator of cytokinesis 2
GAS7 Growth arrest-specific 7
GNA15 Guanine nucleotide-binding protein (G protein), alpha 15 (Gq
class)
HDAC1 Histone deacetylase 1
IDH3A Isocitrate dehydrogenase 3 (NAD+) alpha
IL2RG Interleukin 2 receptor, gamma (severe combined
immunodeficiency)
IMPDH2 IMP (inosine monophosphate) dehydrogenase 2
INPP5D Inositol polyphosphate-5-phosphatase D
LCP1 Lymphocyte cytosolic protein 1 (L-plastin)
LCP2 Lymphocyte cytosolic protein 2 (SH2 domain containing
leukocyte protein of 76kDa)
MAP4K1 Mitogen-activated protein kinase kinase kinase kinase 1
MCM5 MCM5 minichromosome maintenance deficient 5, cell division
cycle 46 (S. cerevisiae)
MYB V-myb myeloblastosis viral oncogene homologue (avian)
MYCBP2 MYC binding protein 2
NCF4 Neutrophil cytosolic factor 4, 40kDa
NUDC Nuclear distribution gene C homolog (A. nidulans)
PENK Proenkephalin
PPIH Peptidyl prolyl isomerase H (cyclophilin H)
RAC2 Ras-related C3 botulinum toxin substrate 2 (rho family, small
GTP-binding protein Rac2)
SLC25A5 Solute carrier family 25 (mitochondrial carrier; adenine
nucleotide translocator), member 5
SLC7A5 Solute carrier family 7 (cationic amino-acid transporter, y+
system), member 5
STAT5A Signal transducer and activator of transcription 5A
TFR2 Transferrin receptor 2
TPBG Trophoblast glycoprotein
WAS Wiskott–Aldrich syndrome (eczema-thrombocytopenia)
The listed genes were selected by the PathwayAssist software as described in the
Results section. An interactive graphical version is available in the supplementary
information online.
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scausal, and that these correlations must be further experimentally
tested and validated.
In comparison to previous similar studies (Scherf et al, 2000;
Dan et al, 2002), we identified other chemosensitivity genes. This
might be explained by several limiting factors as discussed above,
and include differences in cell types, arrays, drugs and assays used.
Even when different arrays were used to study the same samples,
the gene–drug relationships were shown to differ (Scherf et al,
2000; Staunton et al, 2001). Furthermore, in the present study, the
correlation coefficients for the drug–gene correlations were in
general higher than in the previous studies. This might partly be
explained by the inclusion of cell lines selected for drug resistance.
The selection of drug resistance may impose a larger range of gene
expression across samples, leading to higher drug–gene correla-
tion coefficients. This would also potentially increase the
possibility of identifying genes specifically associated with drug
resistance. An advantage of using parental and drug-resistant cell
lines is that the selecting agent and genes specifically involved in
resistance to that particular drug could be isolated. However, it
should be noted that the ability to cluster drugs based on drug–
gene correlations is not limited to drug classes used for drug
resistance selection. Indeed, in the present paper, both the
proteasome inhibitors and Top I inhibitors could be distinguished
as distinct clusters, although no resistant cell lines representative
of these drug classes were included in the panel. Extending the
panel with sublines resistant to mechanistically different drugs
may nevertheless improve the possibility of identifying genes
involved in drug resistance by further increasing the range of
relevant gene expression. We are currently introducing cell lines
resistant to novel target-specific drugs such as proteasome and
tyrosine kinase inhibitors.
In the present study, we employed a molecular pathway analysis
tool, Pathway Assist (www.ariadnegenomics.com), for the analysis
of obtained drug–gene correlations. This procedure allowed quick
and efficient generation of biologically meaningful and literature-
validated relationships between the genes retrieved. PathwayAssist
contains the ResNet database in which more than 500000 events
are recorded and any established pathway can be updated online
by automated mining of Medline using a built-in Natural Language
Processing algorithm (www.ariadnegenomics.com). Performing
such pathway analysis manually would have been extremely time
consuming and laborious. Automated data-mining tools for
pathway analysis will therefore be increasingly important in light
of the exploding information content on molecular pathway
networks.
In conclusion, integration of gene expression and drug activity
data sets for tumour cell line panels provide relationships between
individual gene and drug activity profiles that makes it possible to
identify drug mechanisms of action that can be traced down to
gene level. By also applying powerful software for recognition of
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Figure 5 Analysis of molecular interactions using PathwayAssist. A simplified network for genes associated with resistance is shown. Green lines indicate
positive effects, red lines indicate negative effects and grey lines interactions with unknown effect. Complete interactive graphical versions of the networks
associated with sensitivity and resistance are accessible in supplementary information online and the connections are clickable (dots on lines) to access
hyperlinks to the Medline references on which the networks are based. Clicking on the nodes provides hyperlinks to several gene and protein databases
including HUGO, Locus Link and Swiss-Prot for the particular protein.
Molecular mechanisms for drug resistance
L Rickardson et al
490
British Journal of Cancer (2005) 93(4), 483–492 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
scell signalling pathways, the current approach might accelerate the
drug discovery and evaluation process and provide novel markers
and drug targets for the chemotherapy of cancer. The current
approach is suitable for characterisation of new drugs both with
respect to the mechanism of action and identification of genes
involved in drug sensitivity and resistance.
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